R&D has always been at the core of Grant Technology.
Anti-influenza Drug
Automated Antimicrobial Susceptibility Testing
The antimicrobial susceptibility test by diffusion method was developed in the 1950s. Since then, little has changed with expectation to the development of semi-automated antimicrobial susceptibility test readers which are not at all user friendly. Other “fully automated” methods with a different technology has gained little popularity as manual pretreatment of the sample is required, and limited number of antibiotics can be tested with locked-out reagent cassettes, not to mention a high running cost. As the result, diffusion method by antimicrobial susceptibility discs is still the preferred method in majority of the medical microbiology laboratories worldwide.
We are in development of a new generation fully automated instrument and consumables. The first device to be launched in 2017 is the “ADD” which has been well received in the preview in Medica 2016, Dusseldorf.
mSpectrum
reducing reporting times from days to mere hours
Conventional methods used in microbiology cannot improve reporting times beyond “days”, and thus an innovative approach to bacteria culture and detection is needed. mSpectrum (Microbial Spectrum) is a new technology developed by combining two world recognised methods that are being used today on a daily basis: chromogenic culture media in microbiology laboratories and spectrophotometry in biochemistry laboratories.
The objective of this new technology is to reduce conventional microbiology reporting times from the current 2 to 7 days to 4 to 6 hours. The potential applications of this technology are very diverse, from monitoring contamination in food and environments, to medical microbiology with multi-drug resistant bacteria that require rapid reporting.
COVID-19 Solutions
Grant Technology has been collaborating with global biotech firm BLOK BioScience to develop a suite of products that tackles the challenges presented by the COVID-19 pandemic.
This suite of products is powered by a technology platform built around the core concepts of confidentiality and self-sovereignty.
Travel Bubble
A major hurdle our home market of Hong Kong has yet to overcome is that of unlocking cross-border travel. At present, with very few exceptions, all individuals who enter Hong Kong must undergo quarantine; this not only wreaks havoc on the sectors of the economy most dependent on tourism, but also severely hinders business. One potential solution to this is the establishment of travel bubbles.
Grant Technology is working to adapt BLOK Verify and BLOK Pass—BLOK BioScience’s self-sovereign health status attestation solutions—into tools that enable the creation of travel bubbles. Working with medical centres and businesses all over the world, our aim is initially to create health bubbles within and between corporates and small businesses that use our platform. In time, reciprocal recognition of the BLOK technology platform by businesses will coalesce to form larger health bubbles covering towns, cities, and eventually countries. Our ultimate goal is for BLOK Verify and BLOK Pass to become internationally-recognised standards that make international travel possible once more.
About BLOK BioScience
BLOK BioScience is a global biotech company that provides the technology, supply chain expertise, and protocols for businesses and governments to get our economies back on track during the pandemic—all without compromising the integrity and privacy of individuals.
With offices in the UK, Hong Kong, and Brazil, the company is led by a team of world-class experts, driven by a shared vision of healthier, more prosperous societies.